Wealth Alliance LLC Grows Stake in argenex SE $ARGX

Wealth Alliance LLC grew its stake in shares of argenex SE (NASDAQ:ARGX) by 7.9% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 817 shares of the company’s stock after acquiring an additional 60 shares during the quarter. Wealth Alliance LLC’s holdings in argenex were worth $450,000 as of its most recent SEC filing.

A number of other hedge funds also recently bought and sold shares of ARGX. Bank of New York Mellon Corp grew its position in argenex by 124.5% during the 1st quarter. Bank of New York Mellon Corp now owns 14,283 shares of the company’s stock valued at $8,454,000 after purchasing an additional 7,921 shares during the last quarter. Cerity Partners LLC lifted its stake in shares of argenex by 45.3% in the first quarter. Cerity Partners LLC now owns 4,654 shares of the company’s stock worth $2,755,000 after buying an additional 1,452 shares in the last quarter. Kornitzer Capital Management Inc. KS purchased a new stake in shares of argenex during the first quarter valued at approximately $533,000. Cullen Frost Bankers Inc. lifted its position in argenex by 95.6% in the 1st quarter. Cullen Frost Bankers Inc. now owns 133 shares of the company’s stock valued at $79,000 after acquiring an additional 65 shares in the last quarter. Finally, Morse Asset Management Inc lifted its position in argenex by 98.0% in the 1st quarter. Morse Asset Management Inc now owns 495 shares of the company’s stock valued at $293,000 after acquiring an additional 245 shares in the last quarter. Institutional investors own 60.32% of the company’s stock.

Wall Street Analysts Forecast Growth

ARGX has been the subject of a number of research analyst reports. Wells Fargo & Company lifted their target price on argenex from $741.00 to $756.00 and gave the stock an “overweight” rating in a report on Thursday, July 31st. Royal Bank Of Canada raised their price target on shares of argenex from $850.00 to $860.00 and gave the company an “outperform” rating in a report on Friday, October 31st. Evercore ISI boosted their price objective on shares of argenex from $775.00 to $910.00 and gave the company an “outperform” rating in a report on Friday, October 31st. HC Wainwright increased their price objective on shares of argenex from $774.00 to $915.00 and gave the company a “buy” rating in a research report on Friday, October 31st. Finally, Weiss Ratings restated a “hold (c)” rating on shares of argenex in a report on Wednesday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $879.28.

argenex Price Performance

Shares of NASDAQ:ARGX opened at $891.73 on Friday. The company has a market capitalization of $54.90 billion, a P/E ratio of 38.29, a P/E/G ratio of 0.91 and a beta of 0.45. argenex SE has a 1-year low of $510.05 and a 1-year high of $907.47. The firm’s 50 day simple moving average is $796.20 and its two-hundred day simple moving average is $670.33.

argenex (NASDAQ:ARGX) last announced its quarterly earnings data on Thursday, October 30th. The company reported $4.40 EPS for the quarter, beating the consensus estimate of $4.37 by $0.03. The firm had revenue of $1.12 billion for the quarter, compared to the consensus estimate of $1.07 billion. argenex had a net margin of 41.58% and a return on equity of 29.78%. On average, sell-side analysts anticipate that argenex SE will post 3.13 earnings per share for the current fiscal year.

argenex Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.